LIMN
Liminatus Pharma, Inc. Class A Common Stock
NASDAQ · Healthcare · Biotechnology · US
$3.71
+0.27%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -52.8%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -2.1%
- Net income
- —
- EPS
- -7.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026